- text: We participated in the joint development of mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkinâ€™s lymphoma and other therapeutic areas.
  entities:
    products:
      - mosunetuzumab
    mechanisms:
      - late-stage bispecific antibody
    diseases:
      - B-cell non-Hodgkin's lymphoma
- text: commercialize biosimilar BAT1806, a anti-interleukin-6 (IL-6) receptor monoclonal antibody
  entities:
    products:
      - BAT1806
    classes:
      - biosimilar
    mechanisms:
      - anti-interleukin-6 receptor monoclonal antibody
      - anti-IL-6 receptor monoclonal antibody
- text: A decrease in Fumarate revenue was primarily due to a decrease in TECFIDERA demand as a result of multiple generics entering the market.
  entities:
    products:
      - TECFIDERA
    classes:
      - Fumarate
- text: zuranolone for treatment of MDD, of BIIB124 (SAGE-324) for essential tremor, and BIIB111 (timrepigene emparvovec)
  entities:
    products:
      - zuranolone
      - BIIB124
      - BIIB111
      - timrepigene emparvovec
      - SAGE-324
    diseases:
      - Major Depressive Disorder (MDD)
      - essential tremor
- text: BIIB118 (CK1 inhibitor) - ISWRD in Parkinson's
  entities:
    products:
      - BIIB118
    mechanisms:
      - CK1 inhibitor
    diseases:
      - Parkinson's Disease
      - Irregular Sleep Wake Rhythm Disorder (ISWRD)
- text: Opdivo (nivolumab), a biological product, is a fully human monoclonal antibody that binds to PD-1
  entities:
    products:
      - Opdivo
      - nivolumab
    classes:
      - biological product
    mechanisms:
      - PD-1 monoclonal antibody
- text: GSPT1 CELMoD (CC-90009) --Relapsed/Refractory Acute Myeloid Leukemia
  entities:
    products:
      - GSPT1 CELMoD
      - CC-90009
    diseases:
      - Acute Myeloid Leukemia
      - Relapsed/Refractory Acute Myeloid Leukemia
